We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+4.24%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$5.08B
AUM Growth
-$217M
(-4.1%)
Cap. Flow
+$248M
Cap. Flow
% of AUM
4.88%
Top 10 Holdings %
Top 10 Hldgs %
55.13%
Holding
68
New
14
Increased
10
Reduced
3
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$183M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$92M |
| 3 |
Evolent Health
EVH
|
+$76.1M |
| 4 |
Apogee Therapeutics
APGE
|
+$43.6M |
| 5 |
ARS Pharmaceuticals
SPRY
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$365M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$47.3M |
| 3 |
Cytek Biosciences
CTKB
|
+$44M |
| 4 |
Design Therapeutics
DSGN
|
+$18.7M |
| 5 |
CVAC
CureVac
CVAC
|
+$14.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma A/S
ASND
$16.5B
| $1B | 19.76% |
10,719,555
-505,802
| -5% | -$47.3M |
|
2
Legend Biotech
LEGN
$3.65B
| $421M | 8.28% |
6,264,707
| – | – |
|
3
Vaxcyte
PCVX
$7.65B
| $402M | 7.92% |
7,891,254
| – | – |
|
|
IMGN
4
DELISTED
Immunogen Inc
IMGN
| $211M | 4.16% |
13,322,288
+10,992,330
| +472% | +$183M |
|
|
ETNB
5
DELISTED
89bio
ETNB
| $176M | 3.47% |
11,416,948
| – | – |
|
6
Biogen
BIIB
$30.9B
| $137M | 2.7% |
532,892
| – | – |
|
7
Rhythm Pharmaceuticals
RYTM
$7.31B
| $130M | 2.56% |
5,676,067
| – | – |
|
|
JBIO
8
Jade Biosciences
JBIO
$1.18B
| $112M | 2.21% |
236,114
| – | – |
|
|
CBAY
9
DELISTED
Cymabay Therapeutics
CBAY
| $103M | 2.04% |
+6,940,000
| New | +$92M |
|
|
VRNA
10
DELISTED
Verona Pharma
VRNA
| $103M | 2.03% |
6,317,990
| – | – |
|
11
Tyra Biosciences
TYRA
$1.85B
| $99.6M | 1.96% |
7,236,454
| – | – |
|
12
Wave Life Sciences
WVE
$1.12B
| $98.9M | 1.95% |
17,202,009
| – | – |
|
13
Geron
GERN
$898M
| $97.9M | 1.93% |
46,202,425
+14,657,619
| +46% | +$39.8M |
|
|
DAWN
14
DELISTED
Day One Biopharmaceuticals
DAWN
| $95.8M | 1.89% |
7,809,852
| – | – |
|
15
Janux Therapeutics
JANX
$912M
| $92.4M | 1.82% |
9,165,652
+495,008
| +6% | +$5.71M |
|
16
AN2 Therapeutics
ANTX
$181M
| $89.3M | 1.76% |
5,551,295
+1,777,778
| +47% | +$20.1M |
|
|
INBX
17
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $86.7M | 1.71% |
4,724,207
+870,340
| +23% | +$18.2M |
|
18
RxSight
RXST
$254M
| $85.1M | 1.68% |
3,052,796
| – | – |
|
19
NewAmsterdam Pharma
NAMS
$3.26B
| $83.3M | 1.64% |
9,000,000
| – | – |
|
|
20
Evolent Health
EVH
$371M
| $74.5M | 1.47% |
+2,736,680
| New | +$76.1M |
|
|
CVAC
21
DELISTED
CureVac
CVAC
| $72.4M | 1.43% |
10,604,344
-1,641,611
| -13% | -$14.5M |
|
22
Axsome Therapeutics
AXSM
$11.7B
| $69.9M | 1.38% |
1,000,000
| – | – |
|
23
Cogent Biosciences
COGT
$6.76B
| $62.6M | 1.23% |
6,416,147
| – | – |
|
24
Acumen Pharmaceuticals
ABOS
$152M
| $62M | 1.22% |
14,932,063
+5,161,290
| +53% | +$31.9M |
|
25
Taysha Gene Therapies
TSHA
$1.61B
| $58.4M | 1.15% |
+18,472,503
| New | +$34.5M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, RA Capital Management held 68 positions worth $5.08B, down 4.1% from $5.3B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
RA Capital Management deployed $248M of net new capital in Q3 2023, opening 14 new positions and adding to 10 existing holdings. Its largest new stake was Cymabay Therapeutics: 6,940,000 shares worth $103M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $47.3M trimmed.
- RA Capital Management's largest Q3 2023 buy was Cymabay Therapeutics: 6,940,000 shares worth $103M.
- RA Capital Management added most to Immunogen Inc in Q3 2023, an estimated $183M increase.
- RA Capital Management's biggest Q3 2023 reduction was Ascendis Pharma A/S, cutting an estimated $47.3M.
- RA Capital Management fully exited DICE Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $365M.
- RA Capital Management's ten largest holdings make up 55% of its $5.08B portfolio in Q3 2023.
- RA Capital Management opened 14 new positions and closed 2 in Q3 2023.
- RA Capital Management's portfolio value fell 4.1% quarter-over-quarter to $5.08B.
Based on RA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.